New Drug Shows Pancreatic Cancer Promise

By Bridgette Jacobs

A groundbreaking new drug, daraxonrasib, is showing incredible promise in substantially extending the lives of pancreatic cancer patients by targeting specific cellular proteins that fuel cancer growth. This innovative treatment, which could also impact lung and colon cancers, is currently on fast-track FDA review and might be approved later this year, offering a beacon of hope.

New Drug Shows Pancreatic Cancer Promise

kffhealthnews.org reports: A new drug named daraxonrasib is showing promise in substantially extending the lives of pancreatic cancer patients, as reported by The New York Times.
This innovative drug works by targeting specific cellular proteins that are known to fuel several leading causes of cancer deaths.
The proteins targeted by daraxonrasib are associated with pancreatic, lung, and colon cancers, suggesting a wider potential application.
According to The New York Times, daraxonrasib is currently on a fast-track review by the Food and Drug Administration (FDA).
The drug could potentially receive FDA approval later this year, offering a new treatment option for patients.

Reporting Sources 1